| Damaj, Gandhi |
APHYPAP, NCT03808805: Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms |
|
|
| Recruiting | 3 | 80 | Europe | Aprepitant 80 mg, Hydroxyzine 25mg, Placebo of Hydroxyzine, Placebo of Aprepitant | University Hospital, Brest | Myeloproliferative Disorder, Aquagenic Pruritus | 11/21 | 01/22 | | |
| Recruiting | 2/3 | 463 | Europe, US, RoW | Elenestinib, BLU-263, Placebo | Blueprint Medicines Corporation | Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, Smoldering Systemic Mastocytosis | 06/28 | 06/28 | | |
| Active, not recruiting | 2 | 141 | Europe | Valemetostat tosylate, DS-3201b | The Lymphoma Academic Research Organisation, Daiichi Sankyo | Lymphoma, B-Cell | 10/24 | 10/24 | | |
OASIS-II, NCT04802590: Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma |
|
|
| Recruiting | 2 | 194 | Europe | Ibrutinib 560 mg, Venetoclax 10 MG Oral Tablet [Venclexta], Venetoclax 50 MG Oral Tablet [Venclexta], Venetoclax 100 MG Oral Tablet [Venclexta] | The Lymphoma Academic Research Organisation, Institute of Cancer Research, United Kingdom | Mantle Cell Lymphoma | 03/26 | 09/31 | | |
R-MPV, NCT04446962: LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin |
|
|
| Recruiting | 1/2 | 118 | Europe, RoW | Lenalidomide, Revlimid, Ibrutinib, Imbruvica | Institut Curie, National Cancer Institute, France | Lymphoma, Large B-Cell, Diffuse, Central Nervous System Neoplasms, Primary | 02/25 | 02/35 | | |
NCT02576496: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies |
|
|
| Completed | 1 | 106 | Europe, US | Tinostamustine, EDO-S101 | Mundipharma Research Limited | Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma | 05/23 | 11/23 | | |
| Recruiting | N/A | 100 | Europe | Physical exercises, Optional physical exercises | Centre Hospitalier Universitaire, Amiens, University Hospital, Rouen, University Hospital, Caen | Physical Activity, Multiple Myeloma, Quality of Life | 05/23 | 12/23 | | |
| Recruiting | N/A | 100 | Europe | fundoscopic picture, blood sample, bone marrow sample | Centre Hospitalier Universitaire, Amiens, Centre Hospitalier Saint Vincent, Centre Henri Becquerel, University Hospital, Caen, University Hospital, Lille, Centre Hospitalier de Lens | Hyperviscosity Syndrome, Waldenstrom Macroglobulinemia | 05/24 | 08/24 | | |
SLP-rares, NCT04893564: Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia |
|
|
| Withdrawn | N/A | 90 | Europe | bone marrow sample, blood sample | Centre Hospitalier Universitaire, Amiens, Centre Henri Becquerel, University Hospital, Caen, University Hospital, Lille, Centre Hospitalier de Lens | Waldenstrom's Disease, Waldenstrom Macroglobulinemia | 05/24 | 05/24 | | |
| Recruiting | N/A | 6000 | Europe | Real-life epidemiological platform of lymphoma in France | Hospices Civils de Lyon, The Lymphoma Academic Research Organisation | Diffuse Large B Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), T-cell Lymphoma (T-NHL), Hodgkin's Lymphoma (HL), Burkitt Lymphoma (BL)) | 11/27 | 11/27 | | |
